News

Deal Announcements

Roche Acquires Therapeutic Human Polyclonals

Tuesday, April 3, 2007 6:00:00 AM PDT | VentureDeal
PALO ALTO, CA -- F. Hoffmann-La Roche Ltd. announced the acquisition of biopharmaceutical company Therapeutic Human Polyclonals (THP) for $56.5 million in cash.

THP is an emerging biotech company that focused its research on human antibody technologies.  The company developed a "transgenic mammalian platform to create human antibodies." 

The purpose of the technology is to enable the generation of monoclonal and polyclonal antibodies with enhanced efficacy.


Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1